Literature DB >> 14516520

Acute Treatment of Migraine Headache.

Marcelo E. Bigal1, Richard B. Lipton.   

Abstract

Migraine is a common, chronic neurologic disorder that affects approximately 12% of the adult population in Western countries. Once migraine is diagnosed, illness severity must be assessed. Clinicians and patients should then work together to develop a treatment plan based on patient needs and preferences. The goals of treatment usually include reducing the intensity and duration of acute attacks, minimizing the frequency of attacks, minimizing headache-related disability and maximizing health-related quality of life, and avoiding headache escalation and medication misuse. Management of migraine is divided into pharmacologic and nonpharmacologic approaches. Pharmacologic approaches are subdivided into preventive treatment, taken on a daily basis whether or not headache is present, and acute drugs taken to treat individual attacks as they arise. Acute treatments are further divided into nonspecific agents, which work for all types of pain, and migraine-specific treatments. The US Headache Consortium Guidelines recommend stratified care based on the level of disability to help physicians individualize treatment. Using this approach means that simple analgesics are appropriate as first-line acute treatments for less-disabled patients; if simple analgesics are unsuccessful, treatment is escalated for high-end therapies (eg, triptans). For those with high disability levels, migraine-specific acute therapies, such as the triptans, are recommended as the initial treatment, with preventive drugs in selected patients. A variety of behavioral interventions are helpful. The clinician has an armamentarium of ever-expanding variety of medications. With experience, clinicians can match individual patient needs with the specific characteristics of a drug to optimize therapeutic benefit.

Entities:  

Year:  2003        PMID: 14516520     DOI: 10.1007/s11940-996-0011-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  25 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

2.  Triptans and coronary spasm.

Authors:  K M Welch; J Saiers; R Salonen
Journal:  Clin Pharmacol Ther       Date:  2000-09       Impact factor: 6.875

3.  Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.

Authors:  J H Lofland; N E Johnson; A S Batenhorst; D B Nash
Journal:  Arch Intern Med       Date:  1999-04-26

Review 4.  Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice.

Authors:  J Edmeads; J M Láinez; J L Brandes; J Schoenen; F Freitag
Journal:  Neurology       Date:  2001       Impact factor: 9.910

5.  Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.

Authors:  M D Ferrari; P J Goadsby; K I Roon; R B Lipton
Journal:  Cephalalgia       Date:  2002-10       Impact factor: 6.292

6.  2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study.

Authors:  R B Lipton; W F Stewart; R Cady; C Hall; S O'Quinn; T Kuhn; D Gutterman
Journal:  Headache       Date:  2000 Nov-Dec       Impact factor: 5.887

7.  Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.

Authors:  R B Lipton; W F Stewart; A M Stone; M J Láinez; J P Sawyer
Journal:  JAMA       Date:  2000 Nov 22-29       Impact factor: 56.272

8.  Medical consultation for migraine: results from the American Migraine Study.

Authors:  R B Lipton; W F Stewart; D Simon
Journal:  Headache       Date:  1998-02       Impact factor: 5.887

9.  Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study.

Authors:  P Tfelt-Hansen; J Olesen
Journal:  Cephalalgia       Date:  1984-06       Impact factor: 6.292

Review 10.  Ergotamine and dihydroergotamine: a review.

Authors:  Marcelo E Bigal; Stewart J Tepper
Journal:  Curr Pain Headache Rep       Date:  2003-02
View more
  1 in total

Review 1.  Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life.

Authors:  Dawn C Buse; Marcia F T Rupnow; Richard B Lipton
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.